B+
Bull case
30%
Probability
Target price
$425.00
+15.2% vs current
WAT
WatersCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$395.00
+7.1% vs current
B-
Bear case
20%
Probability
Target price
$320.00
-13.3% vs current
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+66.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+53.0
Score
AI commentary
Primary-source evidence is strong and directionally positive, but the thesis change is still moderate rather than dramatic. The stock’s post-earnings tone appears constructive, consistent with the beat-and-raise, yet by the June 17, 2026 anchor much of that reset likely sits in the price already. News flow after the May 5 print is thin, social context is unavailable, and analyst-revision breadth is incomplete, so this remains a cautious execution-monitoring long rather than a fresh high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05eventQ1 beat-and-raise reset the FY26 bar higherMedium impact
Waters reported Q1 2026 revenue of $1.267 billion, organic constant-currency growth of 11%, adjusted EPS of $2.70, and raised FY26 guidance to 6.5%-8.0% organic constant-currency growth and $14.40-$14.60 adjusted EPS; that moved the debate from whether the BD assets would dilute growth to whether Waters can sustain the higher bar [#SEC-8K-2026-05-05].
2026-12-31catalystBD biosciences and diagnostics integration is the main multi-quarter upside leverMedium impact
The acquired Biosciences and Diagnostic Solutions businesses contributed $520 million of owned-period Q1 revenue, $40 million above guidance, while Waters said revenue synergies were already showing and embedded $15 million of FY26 organic synergy and $35 million of acquired-business synergy into guidance; sustaining that momentum is central to further upside [#SEC-8K-2026-05-05].
2026-12-31catalystExecution must outrun leverage, amortization, and China frictionMedium impact
The 10-Q shows goodwill rising to about $9.3 billion after the acquisition and total debt at about $5.215 billion as of April 4, 2026, while the 10-K and 10-Q continue to flag China procurement, tariff, and competitive risks; that leaves the stock dependent on durable organic instruments/consumables/service demand rather than a one-quarter spike [#SEC-10Q-2026-05-12][#10-K-2026-02-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology